·2088·
李旭，等
依托泊苷联合洛铂与依托泊苷联合顺铂治疗广泛期小细胞肺癌的Meta分析
依托泊苷联合洛铂与依托泊苷联合顺铂治疗广泛期小细胞肺癌的Meta 分析
李旭"2，李楠，廖子君"，李钟瑞"，赵新汉
Etoposidepluslobaplatinversusetoposidepluscisplatinforpatientswithextensivestage smallcell lungcancer:AMeta-analysis
Li Xu'-2 , Li Nan', Liao Zijun', Li Zhongrui' ,Zhao Xinhan?
'Department of First Internal Medicine, Shaanxi Provincial Tumor Hospital , Shaanxi Xi'an 710061, China ;" Department of Medical Oncology,the First Affiliated Hospital of Xi'an Jiaotong Unitersity,Shaanxi Xian 710061, China;'Department of Neurosurgery,Xi'an Childrens Hospital,Shaanxi Xian 710043,China.
[ Abstract] Objective: To evaluate therapeutic efficacy and safety of etoposide plus lobaplatin versus etoposide plus cisplatin chemotherapy for extensive stage small cell lung cancer. Methods: We searched Web of Knowledge, PubMed,The Cochrane Library, CNKI, CBM, VIP and WanFang data base for randomized controlled trials comparing
EL with EP regimens.Literature
Meta analysis w The results of Meta
reened according to Cochrane Handbook 5. 0. 1 quality evaluation criteria.
conducted with RevMa
two groups in the effective
teOR
significant difference between EL regimel
08.954
Results: Four RCTs were included,involving 401 patients.
eflicacy.there
was no significant difference between the
0. 82]. In the aspect of safety, there was
and EP regimen in grade II IV nausea/ vomiting [OR =0.34,95% CI
were no significant difference between the two groups in the grade II IV neu-
(0. 20 ~0. 58) ,P <0. 000 1]. There
tropenia [ OR =0. 77,95% CI(0. 37 ~1. 63) ,P = 0.50] ,grade I IV thromboeytopenia[ OR = 2. 81,95% CI(0. 74 ~ 10. 68) ,P =0. 13] ,grade II IV anemia [ OR = 0. 47,95% CI(0. 08 ~ 2. 67) ,P = 0. 40]. Conclusion: EL has similar efficacy to EP for extensive stage small cell lung cancer patients,but it has fewer side effects of nausea/vomi ting, It is well tolerant.
[Key words] small cell lung cancer,etoposide,lobaplatin,Meta analysis
Moderm Oncology 2016,24(13) :2088 2092
【摘要】目
目的：系统评价依托泊替联合洛铂(EL）与依托泊苷联合顺铂（EP)治疗广泛期小细胞肺癌的有效性
和安全性。方法：计算机检索Web of Knowledge、PubMed、The Cochrane Library、CBM、CNKI、VIP及WanFang Data关于EL方案与EP方案治疗广泛期小细胞肺癌的随机对照研究（RCT）。依据CochraneHandbook5.0.1 的质量评价标准进行RCT筛选、资料提取和质量评价后，采用RevMan5.2软件进行Meta分析。结果：共纳人4篇RCT研究，共计401例患者，Meta分析结果显示：在疗效方面，EL方案与EP方案相比，两者有效率差异无统计学意义[ORR=1.08,95%CI(0.53~2.21）,P=0.82]。在安全性方面，EL方案与EP方案相比，Ⅲ-IV度消化道反应发生率差异具有统计学意义[0R=0.34,95%CI(0.20~0.58),P<0.0001]。而在Ⅲ-IV 度白细胞减少[OR=0.77,95%CI(0.37~1.63),P=0.50],Ⅲ-IV度血小板减少[OR=2.81,95%CI(0.74~ 10.68）,P=0.13]，耳-IV度贫血[0R=0.47,95%CI(0.08~2.67),P=0.40]等方面差异无统计学意义。结
论：EL方案在疗效方面与EP方案大致相当，EL方案消化道反应轻，患者耐受性好。【关键调】小细胞肺癌；依托泊苷；洛铂；Meta分析
【中图分类号】R734.2
【文献标识码】A
【文章编号】16724992(201613208805
【收稿日期】2016-02-14
【作者单位】【作者简介】【通讯作者】
"陕西省肿瘤医院内一科，陕西西安710061
"西安交通大学医学院第附属医院肿瘤内科，陕西
DOI:10.3969/j. issn. 1672 4992.2016. 13.022
西安710061
"西安市儿童医院神经外科，陕西西安710043
李旭（1982-），男，陕西户县人，主治医师，在读博士，主要从事肿瘤的循证综合治疗工作。E-mail；lixu0204@sohu，com 赵新汉（1964-），男，陕西眉县人，主任医师，教授，博士生导师，主要从事肿瘤的综合治疗研究。